Warby Parker (WRBY)
(Delayed Data from NYSE)
$16.54 USD
+0.51 (3.18%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $16.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Warby Parker Inc. (WRBY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$16.45 | $20.00 | $14.00 | 2.62% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Warby Parker Inc. comes to $16.45. The forecasts range from a low of $14.00 to a high of $20.00. The average price target represents an increase of 2.62% from the last closing price of $16.03.
Analyst Price Targets (11)
Broker Rating
Warby Parker Inc. currently has an average brokerage recommendation (ABR) of 2.23 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 2.23 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, five are Strong Buy, representing 38.46% of all recommendations. A month ago, Strong Buy represented 38.46%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 8 | 8 | 8 | 8 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.23 | 2.23 | 2.23 | 2.23 | 2.23 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/30/2024 | Goldman Sachs | Brooke Roach | Hold | Hold |
5/10/2024 | Not Identified | Not Identified | Hold | Hold |
5/10/2024 | UBS | Mark Carden | Hold | Hold |
5/10/2024 | Loop Capital Markets | Anthony C Chukumba | Hold | Hold |
5/9/2024 | Telsey Advisory Group | Dana Telsey | Strong Buy | Strong Buy |
4/30/2024 | William Blair | Dylan Carden | Hold | Hold |
4/1/2024 | Cowen & Co. | Oliver Chen | Strong Buy | Strong Buy |
2/29/2024 | Not Identified | Not Identified | Hold | Hold |
2/29/2024 | JMP Securities | Nicholas Jones | Hold | Hold |
2/1/2024 | Robert W. Baird & Co. | Mark R Altschwager | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Janine Stichter | Strong Buy | Strong Buy |
10/3/2023 | Evercore Partners | Mark Mahaney | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.23 |
ABR (Last week) | 2.23 |
# of Recs in ABR | 13 |
Average Target Price | $16.45 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 98 of 252 |
Current Quarter EPS Est: | 0.05 |